Femasys To Participate in Upcoming BTIG Biotechnology Conference

ATLANTA, Aug. 03, 2022 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company’s management team will be participating in one-on-one meetings virtually at the upcoming BTIG Biotechnology Conference. The conference, which will be held on a hybrid basis, is taking place at the St. Regis New York Hotel in in New York City on August 8-9, 2022.

If you are interested in meeting with Femasys at the conference, please reach out to your BTIG representative to schedule a meeting.

About Femasys
Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, is currently marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv^®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
[email protected]

Media
Karissa Cross, Ph.D.
LifeSci Communications
[email protected]

Femasys Inc.
Investor Contact:
[email protected]

Media Contact:
[email protected]